231 related articles for article (PubMed ID: 17626034)
1. The endocannabinoid system is dysregulated in multiple sclerosis and in experimental autoimmune encephalomyelitis.
Centonze D; Bari M; Rossi S; Prosperetti C; Furlan R; Fezza F; De Chiara V; Battistini L; Bernardi G; Bernardini S; Martino G; Maccarrone M
Brain; 2007 Oct; 130(Pt 10):2543-53. PubMed ID: 17626034
[TBL] [Abstract][Full Text] [Related]
2. Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis.
Cabranes A; Venderova K; de Lago E; Fezza F; Sánchez A; Mestre L; Valenti M; García-Merino A; Ramos JA; Di Marzo V; Fernández-Ruiz J
Neurobiol Dis; 2005 Nov; 20(2):207-17. PubMed ID: 16242629
[TBL] [Abstract][Full Text] [Related]
3. Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis.
Rossi S; Furlan R; De Chiara V; Muzio L; Musella A; Motta C; Studer V; Cavasinni F; Bernardi G; Martino G; Cravatt BF; Lutz B; Maccarrone M; Centonze D
Brain Behav Immun; 2011 Aug; 25(6):1242-8. PubMed ID: 21473912
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid levels of the endocannabinoid anandamide are reduced in patients with untreated newly diagnosed temporal lobe epilepsy.
Romigi A; Bari M; Placidi F; Marciani MG; Malaponti M; Torelli F; Izzi F; Prosperetti C; Zannino S; Corte F; Chiaramonte C; Maccarrone M
Epilepsia; 2010 May; 51(5):768-72. PubMed ID: 19817812
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis.
Di Filippo M; Pini LA; Pelliccioli GP; Calabresi P; Sarchielli P
J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1224-9. PubMed ID: 18535023
[TBL] [Abstract][Full Text] [Related]
6. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum.
Maccarrone M; Rossi S; Bari M; De Chiara V; Fezza F; Musella A; Gasperi V; Prosperetti C; Bernardi G; Finazzi-Agrò A; Cravatt BF; Centonze D
Nat Neurosci; 2008 Feb; 11(2):152-9. PubMed ID: 18204441
[TBL] [Abstract][Full Text] [Related]
7. Endocannabinoids control spasticity in a multiple sclerosis model.
Baker D; Pryce G; Croxford JL; Brown P; Pertwee RG; Makriyannis A; Khanolkar A; Layward L; Fezza F; Bisogno T; Di Marzo V
FASEB J; 2001 Feb; 15(2):300-2. PubMed ID: 11156943
[TBL] [Abstract][Full Text] [Related]
8. Gene Expression Analysis of Astrocyte and Microglia Endocannabinoid Signaling during Autoimmune Demyelination.
Moreno-García Á; Bernal-Chico A; Colomer T; Rodríguez-Antigüedad A; Matute C; Mato S
Biomolecules; 2020 Aug; 10(9):. PubMed ID: 32846891
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells.
Eljaschewitsch E; Witting A; Mawrin C; Lee T; Schmidt PM; Wolf S; Hoertnagl H; Raine CS; Schneider-Stock R; Nitsch R; Ullrich O
Neuron; 2006 Jan; 49(1):67-79. PubMed ID: 16387640
[TBL] [Abstract][Full Text] [Related]
10. Endocannabinoids in chronic migraine: CSF findings suggest a system failure.
Sarchielli P; Pini LA; Coppola F; Rossi C; Baldi A; Mancini ML; Calabresi P
Neuropsychopharmacology; 2007 Jun; 32(6):1384-90. PubMed ID: 17119542
[TBL] [Abstract][Full Text] [Related]
11. Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis.
Lourbopoulos A; Grigoriadis N; Lagoudaki R; Touloumi O; Polyzoidou E; Mavromatis I; Tascos N; Breuer A; Ovadia H; Karussis D; Shohami E; Mechoulam R; Simeonidou C
Brain Res; 2011 May; 1390():126-41. PubMed ID: 21406188
[TBL] [Abstract][Full Text] [Related]
12. The endocannabinoid system in neurodegeneration.
Battista N; Fezza F; Finazzi-Agrò A; Maccarrone M
Ital J Biochem; 2006; 55(3-4):283-9. PubMed ID: 17274532
[TBL] [Abstract][Full Text] [Related]
13. Effect of an acute consumption of a moderate amount of ethanol on plasma endocannabinoid levels in humans.
Feuerecker M; Hauer D; Gresset T; Lassas S; Kaufmann I; Vogeser M; Briegel J; Hornuss C; Choukèr A; Schelling G
Alcohol Alcohol; 2012; 47(3):226-32. PubMed ID: 22278319
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis may disrupt endocannabinoid brain protection mechanism.
Shohami E; Mechoulam R
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6087-8. PubMed ID: 16606822
[No Abstract] [Full Text] [Related]
15. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol.
Spoto B; Fezza F; Parlongo G; Battista N; Sgro' E; Gasperi V; Zoccali C; Maccarrone M
Biochimie; 2006 Dec; 88(12):1889-97. PubMed ID: 16949718
[TBL] [Abstract][Full Text] [Related]
16. The endocannabinoid anandamide downregulates IL-23 and IL-12 subunits in a viral model of multiple sclerosis: evidence for a cross-talk between IL-12p70/IL-23 axis and IL-10 in microglial cells.
Correa F; Hernangómez-Herrero M; Mestre L; Loría F; Docagne F; Guaza C
Brain Behav Immun; 2011 May; 25(4):736-49. PubMed ID: 21310228
[TBL] [Abstract][Full Text] [Related]
17. Plasma endocannabinoid levels in multiple sclerosis.
Jean-Gilles L; Feng S; Tench CR; Chapman V; Kendall DA; Barrett DA; Constantinescu CS
J Neurol Sci; 2009 Dec; 287(1-2):212-5. PubMed ID: 19695579
[TBL] [Abstract][Full Text] [Related]
18. Intense exercise increases circulating endocannabinoid and BDNF levels in humans--possible implications for reward and depression.
Heyman E; Gamelin FX; Goekint M; Piscitelli F; Roelands B; Leclair E; Di Marzo V; Meeusen R
Psychoneuroendocrinology; 2012 Jun; 37(6):844-51. PubMed ID: 22029953
[TBL] [Abstract][Full Text] [Related]
19. Quantification of anandamide and 2-arachidonoylglycerol plasma levels to examine potential influences of tetrahydrocannabinol application on the endocannabinoid system in humans.
Thieme U; Schelling G; Hauer D; Greif R; Dame T; Laubender RP; Bernhard W; Thieme D; Campolongo P; Theiler L
Drug Test Anal; 2014; 6(1-2):17-23. PubMed ID: 24424856
[TBL] [Abstract][Full Text] [Related]
20. Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
Ruffini F; Rossi S; Bergamaschi A; Brambilla E; Finardi A; Motta C; Studer V; Barbieri F; De Chiara V; Hayardeny L; Comi G; Centonze D; Martino G
Mult Scler; 2013 Jul; 19(8):1084-94. PubMed ID: 23232603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
